Facebook
Twitter
LinkedIn
Email
 |
Checking for direct PDF access through Ovid | |
Excerpt
Moderate exercise training is believed to enhance certain aspects of the adaptive immune system. However, it is uncertain how chronic exposure to a transplanted prostate cancer may affect the immune system of a trained animal. This study examined the effects of voluntary wheel running on the percentage of splenic lymphocyte subpopulations in rats with transplanted prostate cancer. Animals were randomly assigned to running wheel (RW:n=10) or control (C:n=9) groups. The RW animals were given free access to the running wheels for 11 weeks. At the start of week 12, all animals were inoculated with 1×106 transplantable rat prostate cancer cells subcutaneously on the back. The RW animals were sacrificed at the conclusion of week 19. Splenocytes were collected and first stained with FITC or Biotin conjugated antibodies, then with Phycoerythrin (PE) or Streptavidin-CyChrome secondary reagents. Gated lymphocytes were electronically characterized by Fluorescence intensity in all 3 stains (FITC, Biotin-Avidin, PE), two stains at a time: FITC×BA, FITC×PE, BA×PE. Results are reported as percent positive for individually-stained subpopulations (T helper, CD4; T cytotoxic, CD8; macrophages, MO; B cells), percent of each subpopulations which also bore an activation marker [Interleukin-2 receptor (IL2R), MHCH], and for two subpopulations that bore the same activation marker. Results: C had a greater (p<0.05) percentage of MO, activated MO and activated cells (CD4+IL2R and CD8+IL2R). C tended (p=0.07) to have higher levels of activated B and MO (B+MHCH, MO+MHCH) and percentage of CD4+IL2R cells. However, RW tended (p=0.07) to have a higher percentage of CD8 cells. No difference was observed in the percentage of total CD4 or B cells. Conclusion: Voluntary running-wheel exercise for 19 weeks appeared to suppress a certain percentage of splenocyte cells (MO, activated MO and CD4+IL2R and CD8+IL2R) involved in antigen-specific responses capable of modifying tumor growth in rats with prostate cancer.
